BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 04, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/1 cls
Celsion Corp. (NASDAQ:CLSN) Roth Capital Partners Joseph Pantginis Downgrade Neutral (from buy) -83% $1.32
Pantginis also lowered his target to $1.70 from $10 after Celsion announced that its IV ThermoDox failed in the Phase III HEAT trial to treat non-resectable hepatocellular carcinoma (HCC) (see B18). He said his target is now based solely on the Phase II study of ThermoDox in recurrent chest wall breast cancer, and assigns a 10% chance of success in this indication. The product is doxorubicin encapsulated in a heat-activated liposome.
Furiex Pharmaceuticals Inc. (NASDAQ:FURX) Canaccord Randall Stanicky New Buy 61% $34.21
Stanicky initiated coverage with a $45 target after FDA approved three Type II diabetes products - Nesina alogliptin, Kazano alogliptin/metformin and Oseni alogliptin/pioglitazone - from partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Stanicky sees highly visible cash flow on royalties and milestones for Furiex mainly from Nesina, which Takeda already markets...

Read the full 1018 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >